NovaBay Pharmaceuticals, Inc. (NBY) Financial Statements
Industry: Finance Services
In fiscal 2025, NovaBay Pharmaceuticals reported revenue of $0, down 100.0% from $9.8M the year before. Net income was -$22.1M. Operating activities generated -$8.4M of cash. At fiscal year end, NovaBay Pharmaceuticals held $9.0M in total assets against $31.9M in total liabilities, including $8.0M of cash and equivalents.
Open the full interactive NovaBay Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
NovaBay Pharmaceuticals Key Stats
| Share Price | $1.25 |
|---|---|
| Market Cap | $38.8M |
| Dividend Yield | 12.41% |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $0.84 – $95.80 |
| Shares Outstanding | 31.0 million (basic, 2026 Q2) |
NovaBay Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $9.9M | $8.4M | $14.4M | $14.7M | $9.8M | $0 |
| Cost of Goods Sold | $4.0M | $2.8M | $6.6M | $6.8M | $3.3M | — |
| Gross Profit | $6.0M | $5.6M | $7.8M | $7.9M | $6.5M | — |
| Operating Income | -$6.4M | -$8.9M | -$14.4M | -$7.6M | -$5.8M | -$8.4M |
| Pre-Tax Income | -$11.0M | -$5.8M | -$10.6M | -$9.6M | -$7.2M | -$22.1M |
| Income Tax | $5,000 | $0 | $0 | — | $0 | $0 |
| Net Income | -$11.0M | -$5.8M | -$10.6M | -$9.6M | -$7.2M | -$22.1M |
| Diluted EPS | -$1898.75 | -$918.75 | — | — | — | — |
NovaBay Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $521,000 | — | $2.5M | $2.2M |
| Net Income | -$1.3M | -$26.6M | $552.4M | -$41.1M |
| Diluted EPS | -$1.10 | — | $3.33 | -$1.32 |
NovaBay Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.0M | $7.5M | $5.4M | $3.1M | $430,000 | $8.0M |
| Current Assets | $14.2M | $13.2M | $11.3M | $7.2M | $1.9M | $8.7M |
| Total Assets | $15.2M | $24.0M | $16.4M | $9.0M | $3.4M | $9.0M |
| Current Liabilities | $2.8M | $3.4M | $4.3M | $4.3M | $2.8M | $1.1M |
| Total Liabilities | $2.9M | $13.8M | $5.8M | $5.7M | $3.6M | $31.9M |
| Shareholders' Equity | $12.3M | $10.2M | $10.6M | $3.3M | -$129,000 | -$23.2M |
NovaBay Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$4.7M | -$9.2M | -$6.7M | -$4.1M | -$5.2M | -$8.4M |
| Cash From Investing | -$26,000 | -$12.0M | -$112,000 | -$19,000 | $1.1M | — |
| Cash From Financing | $9.8M | $16.8M | $4.6M | $1.9M | $1.5M | $4.6M |
| Free Cash Flow | -$4.7M | -$9.2M | -$6.8M | -$4.2M | -$5.2M | — |
| Dividends Paid | — | — | — | — | — | $4.8M |
Figures from NovaBay Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full NovaBay Pharmaceuticals financials page for every line item.
NovaBay Pharmaceuticals Company Profile
| Ticker | NBY |
|---|---|
| Exchange | NYSE |
| Industry | Finance Services |
| Headquarters | West Palm Beach, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001389545 |
Frequently Asked Questions
What was NovaBay Pharmaceuticals' revenue in fiscal 2025?
NovaBay Pharmaceuticals (NBY) reported revenue of $0 for fiscal 2025.
What is NovaBay Pharmaceuticals' annual revenue history?
NovaBay Pharmaceuticals' annual revenue by fiscal year: 2020: $9.9M; 2021: $8.4M; 2022: $14.4M; 2023: $14.7M; 2024: $9.8M; 2025: $0.
What was NovaBay Pharmaceuticals' net income in fiscal 2025?
NovaBay Pharmaceuticals reported net income of -$22.1M for fiscal 2025.
What was NovaBay Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), NovaBay Pharmaceuticals reported revenue of $2.2M.
How many shares of NovaBay Pharmaceuticals are outstanding?
NovaBay Pharmaceuticals reported a weighted average of 31.0 million basic shares outstanding in 2026 Q2.
What is NovaBay Pharmaceuticals' market cap?
Based on its latest closing price, NovaBay Pharmaceuticals (NBY) has a market capitalization of about $38.8M.
When does NovaBay Pharmaceuticals' fiscal year end?
NovaBay Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is NovaBay Pharmaceuticals headquartered?
NovaBay Pharmaceuticals lists its business address in West Palm Beach, Florida in its SEC filings.